National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Osimertinib (Tagrisso®) as monotherapy for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations.

NCPE Assessment Process Complete
Rapid review commissioned 19/07/2018
Rapid review completed 07/08/2018
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of osimertinib for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with activating EGFR mutations compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 28/08/2018
Pre-submission consultation with Applicant 08/10/2018
Submission received from Applicant 21/01/2019
Preliminary review sent to Applicant 13/05/2019
NCPE assessment re-commenced 28/05/2019
Factual accuracy sent to Applicant 19/07/2019
NCPE assessment re-commenced 30/07/2019
NCPE assessment completed 06/08/2019
NCPE assessment outcome The NCPE recommends that osimertinib not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

Summary